Ingalls & Snyder LLC Cuts Position in Supernus Pharmaceuticals Inc (NASDAQ:SUPN)

Share on StockTwits

Ingalls & Snyder LLC cut its stake in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 59.6% in the 4th quarter, Holdings Channel reports. The fund owned 70,688 shares of the specialty pharmaceutical company’s stock after selling 104,200 shares during the quarter. Ingalls & Snyder LLC’s holdings in Supernus Pharmaceuticals were worth $1,677,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Renaissance Group LLC boosted its position in Supernus Pharmaceuticals by 3.8% during the third quarter. Renaissance Group LLC now owns 10,496 shares of the specialty pharmaceutical company’s stock valued at $288,000 after buying an additional 380 shares during the period. First Mercantile Trust Co. boosted its position in Supernus Pharmaceuticals by 31.5% during the third quarter. First Mercantile Trust Co. now owns 2,173 shares of the specialty pharmaceutical company’s stock valued at $60,000 after buying an additional 520 shares during the period. Nisa Investment Advisors LLC boosted its position in Supernus Pharmaceuticals by 6.5% during the third quarter. Nisa Investment Advisors LLC now owns 9,770 shares of the specialty pharmaceutical company’s stock valued at $268,000 after buying an additional 593 shares during the period. Private Capital Group LLC boosted its position in Supernus Pharmaceuticals by 108.0% during the second quarter. Private Capital Group LLC now owns 1,379 shares of the specialty pharmaceutical company’s stock valued at $83,000 after buying an additional 716 shares during the period. Finally, California State Teachers Retirement System boosted its position in Supernus Pharmaceuticals by 1.2% during the third quarter. California State Teachers Retirement System now owns 76,841 shares of the specialty pharmaceutical company’s stock valued at $2,112,000 after buying an additional 917 shares during the period. Institutional investors own 94.95% of the company’s stock.

Several analysts have issued reports on SUPN shares. ValuEngine upgraded shares of Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, December 3rd. Stifel Nicolaus lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price target for the company from $55.00 to $23.00 in a research report on Thursday, November 7th. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 9th. Berenberg Bank lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, BidaskClub upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Supernus Pharmaceuticals has an average rating of “Hold” and an average target price of $46.50.

SUPN stock opened at $24.58 on Thursday. Supernus Pharmaceuticals Inc has a 1 year low of $19.35 and a 1 year high of $43.05. The company has a market cap of $1.25 billion, a P/E ratio of 11.99, a PEG ratio of 1.25 and a beta of 1.50. The firm has a 50-day moving average of $23.29 and a 200 day moving average of $26.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.85 and a quick ratio of 2.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $0.54 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.59 by ($0.05). Supernus Pharmaceuticals had a return on equity of 21.02% and a net margin of 25.92%. The company had revenue of $102.14 million during the quarter, compared to the consensus estimate of $108.70 million. During the same period in the previous year, the company earned $0.52 earnings per share. Supernus Pharmaceuticals’s quarterly revenue was down .8% on a year-over-year basis. On average, equities research analysts expect that Supernus Pharmaceuticals Inc will post 2.06 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Featured Story: What is the S&P/ASX 200 Index?

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Assenagon Asset Management S.A. Has $2.34 Million Position in Archer Daniels Midland Co
Assenagon Asset Management S.A. Has $2.34 Million Position in Archer Daniels Midland Co
Assenagon Asset Management S.A. Raises Holdings in Mid-America Apartment Communities Inc
Assenagon Asset Management S.A. Raises Holdings in Mid-America Apartment Communities Inc
Assenagon Asset Management S.A. Lowers Holdings in DTE Energy Co
Assenagon Asset Management S.A. Lowers Holdings in DTE Energy Co
Assenagon Asset Management S.A. Purchases 5,080 Shares of Willis Towers Watson PLC
Assenagon Asset Management S.A. Purchases 5,080 Shares of Willis Towers Watson PLC
Commerzbank Aktiengesellschaft FI Grows Stock Position in S&P Global Inc
Commerzbank Aktiengesellschaft FI Grows Stock Position in S&P Global Inc
Microsoft Co.  Position Reduced by Argus Investors Counsel Inc.
Microsoft Co. Position Reduced by Argus Investors Counsel Inc.


 
© 2006-2020 Zolmax.